Skip to content
lifestyle.capitolhilltimes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Formation Bio
Formation Bio Appoints Michael Ehlers as Chief Scientific Officer and Head of R&D
July 22, 2026
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
June 9, 2026
Formation Bio Licenses miR-124 Activator for Autoimmune Diseases from CTFH
January 29, 2026